PL3484469T3 - Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych - Google Patents

Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych

Info

Publication number
PL3484469T3
PL3484469T3 PL17827133.4T PL17827133T PL3484469T3 PL 3484469 T3 PL3484469 T3 PL 3484469T3 PL 17827133 T PL17827133 T PL 17827133T PL 3484469 T3 PL3484469 T3 PL 3484469T3
Authority
PL
Poland
Prior art keywords
potentiating
antimicrobials
compositions
methods
potentiating antimicrobials
Prior art date
Application number
PL17827133.4T
Other languages
English (en)
Inventor
Ephraim Brener
Elran HABER
Adi Zuloff-Shani
Ascher Shmulewitz
Original Assignee
Scisparc Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scisparc Ltd filed Critical Scisparc Ltd
Publication of PL3484469T3 publication Critical patent/PL3484469T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065Diphenyl-substituted acyclic alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17827133.4T 2016-07-14 2017-07-13 Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych PL3484469T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662362082P 2016-07-14 2016-07-14
PCT/IL2017/050800 WO2018011813A1 (en) 2016-07-14 2017-07-13 Compositions and methods of potentiating antimicrobials

Publications (1)

Publication Number Publication Date
PL3484469T3 true PL3484469T3 (pl) 2024-08-19

Family

ID=60952228

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17827133.4T PL3484469T3 (pl) 2016-07-14 2017-07-13 Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych

Country Status (9)

Country Link
US (3) US20190183914A1 (pl)
EP (1) EP3484469B1 (pl)
CN (3) CN119770661A (pl)
CA (1) CA3068806A1 (pl)
DK (1) DK3484469T3 (pl)
ES (1) ES2985112T3 (pl)
MA (1) MA45688A (pl)
PL (1) PL3484469T3 (pl)
WO (1) WO2018011813A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352855A4 (en) 2015-09-22 2019-05-22 Vitality Biopharma, Inc. CANNABINOID GLYCOSIDE PRODRUGS AND SYNTHESIS METHOD
CA3063186A1 (en) 2017-05-09 2018-11-15 Vitality Biopharma, Inc. Antimicrobial compositions comprising cannabinoids and methods of using the same
US12198788B2 (en) * 2017-10-04 2025-01-14 Cannibite Bvba System for detecting an intraoral disease and determining a personalized treatment scheme and method of doing same
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
WO2020051284A1 (en) * 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
WO2020089902A1 (en) * 2018-10-30 2020-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions comprising cannabinoids for use in the treatment of biofilm and conditions associated with microbial, fungal, bacterial infections
GB2581987B (en) * 2019-03-06 2021-11-17 Gw Res Ltd Use of cannabidiol in combination with antibiotics
EP3946315A4 (en) * 2019-03-28 2023-04-12 Scicann Therapeutics Inc. CANNABINOID COMPOSITIONS AND USE THEREOF
CN109758441A (zh) * 2019-03-29 2019-05-17 广东工业大学 N-脂肪酰基乙醇胺类化合物在制备抑制细菌群体感应系统的药物中的应用和药物
CN113710263A (zh) 2019-05-06 2021-11-26 大不列颠哥伦比亚大学 抗生大麻素-萜烯制剂
CA3143338A1 (en) * 2019-06-18 2020-12-24 Botanix Pharmaceuticals Limited Antibacterial dosage regime using cannabinoids
US12257307B2 (en) 2019-06-24 2025-03-25 Diverse Biotech, Inc. β-lactam-cannabinoid conjugate molecules
CN110973159B (zh) * 2019-10-30 2021-04-06 广州市浪奇实业股份有限公司 一种含有大麻二酚的抗菌组合物及其应用
CN115066234A (zh) * 2019-11-29 2022-09-16 博塔尼克斯药物有限公司 使用大麻素和活性剂的抗菌治疗
CN112195558A (zh) * 2020-09-24 2021-01-08 上海丰格无纺布有限公司 一种抗微生物无纺布及其制备方法
WO2023130142A2 (en) * 2022-01-03 2023-07-06 Bryant Cynthia W Compositions and methods using cannabinoid compounds for treating urinary tract disorders
WO2024159198A2 (en) * 2023-01-27 2024-08-02 Nagy Aurangzeb Nafees Compositions and methods using tetrahydrocannabinol and compositions including same for treating indications involving inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506224A (en) 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
CA2330681C (en) 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
US20050054730A1 (en) 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
US9192598B2 (en) * 2008-06-25 2015-11-24 University Of North Texas Health Science Center At Fort Worth Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
CN103361820A (zh) * 2012-03-30 2013-10-23 太仓棨淂服装有限公司 一种抗菌牛仔面料
AU2014324691A1 (en) * 2013-09-26 2016-04-21 Ronald D. Sekura Topical treatments incorporating cannabis sp. derived botanical drug product

Also Published As

Publication number Publication date
US20230045747A1 (en) 2023-02-09
MA45688A (fr) 2019-05-22
ES2985112T3 (es) 2024-11-04
EP3484469A1 (en) 2019-05-22
CA3068806A1 (en) 2018-01-18
DK3484469T3 (da) 2024-06-24
CN119633002A (zh) 2025-03-18
CN109562094A (zh) 2019-04-02
CN119770661A (zh) 2025-04-08
US20210093652A1 (en) 2021-04-01
EP3484469A4 (en) 2020-07-22
WO2018011813A1 (en) 2018-01-18
US11491172B2 (en) 2022-11-08
EP3484469B1 (en) 2024-05-22
US20190183914A1 (en) 2019-06-20
US12533370B2 (en) 2026-01-27

Similar Documents

Publication Publication Date Title
PL3484469T3 (pl) Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
ZA201801511B (en) Flavonoid compositions and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
SI3102555T1 (sl) Sestavki spojin in njihove uporabe
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
ZA201701909B (en) Trichoderma compositions and methods of use
PL3349743T3 (pl) Sposoby i kompozycje do hamowania oddziaływania dcn1-ubc12
PT3319609T (pt) Composições e métodos de uso de combinações de fármacos antibacterianos
IL257458A (en) dpep-1 binding compositions and methods of use
PL3145480T3 (pl) Przygotowane bezpośrednio przed użyciem kompozycje kosmetyczne i/lub dermatologiczne
GB201608762D0 (en) Compositions and uses thereof
GB201715820D0 (en) Compositions and methods
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
PT3503885T (pt) Composição farmacêutica e métodos de utilização
GB201621737D0 (en) Compositions and methods of treatment
GB201607910D0 (en) Microparticles and composition
IL261794A (en) Preparations and methods for using them
PL3445730T3 (pl) Makrokompozyty i kompozycje z kamienia i szkła oraz sposoby wytwarzania
GB201614897D0 (en) Compositions and uses thereof
ZA201706950B (en) Antibacterial compositions and methods
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
GB201602409D0 (en) Compositions and uses thereof